Crossmark

Cost-effectiveness of preemptive skin treatment to prevent skin-toxicity caused by panitumumab in third-line therapy for KRAS wild type metastatic colorectal cancer in Japan

Crossref DOI link: https://doi.org/10.1186/s40780-021-00218-7

Published Online: 2021-10-01

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Kashiwa, Munenobu https://orcid.org/0000-0001-5178-611X
Matsushita, Ryo
License Information

Text and Data Mining valid from 2021-10-01

Version of Record valid from 2021-10-01
More Information

Article History

Received: 7 June 2021

Accepted: 2 August 2021

First Online: 1 October 2021

Declarations

:

: Not applicable.

: Not applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below